Provention details pipeline

Provention Bio Inc. (Lebanon, N.J.), a newco pursuing autoimmune and inflammatory disease therapies, disclosed details on Thursday regarding two in-licensed programs from the Janssen unit of Johnson & Johnson (NYSE:JNJ).

Provention holds exclusive, worldwide rights to PRV-6527 (JNJ-40346527), an oral colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115) inhibitor, to treat inflammatory bowel disease (IBD) and to PRV-300 (JNJ-42915925), a toll-like receptor 3 (TLR3) mAb, for all indications. ...